BTG.L on London Stock Exchange

27 Oct 2016
Change (% chg)

-4.00p (-0.59%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low


Chart for BTG.L


BTG plc is engaged in the business of healthcare, focusing on Interventional Medicine therapies for liver cancer, emphysema and vascular disorders, specialty pharmaceuticals for acute care uses, and a licensing business. The Company operates through three segments: Interventional Medicine, Specialty Pharmaceuticals and... (more)


Beta: 0.09
Market Cap(Mil.): £2,616.51
Shares Outstanding(Mil.): 385.06
Dividend: --
Yield (%): --


  BTG.L Industry Sector
P/E (TTM): 43.60 33.59 33.70
EPS (TTM): 0.16 -- --
ROI: 6.19 14.39 13.89
ROE: 7.53 15.20 14.85

British healthcare firm BTG settles DoJ probe into U.S. unit

Oct 6 British healthcare group BTG Plc said it agreed to settle an investigation into one of its U.S. units, Biocompatibles, with the U.S. Department of Justice for $36 million.

06 Oct 2016

BRIEF-BTG's Biocompatibles to settle LC Bead probe for $36 mln

* Unit Biocompatibles subsidiary reached a settlement with U.S. government in relation to department of justice's investigation of marketing of LC Bead

06 Oct 2016

CORRECTED-BRIEF-BTG raises revenue guidance on boost from the weaker pound

* On basis of current foreign exchange rates, reported full year revenue is now anticipated to be ahead of our previously announced guidance range of £510m-£540m

06 Oct 2016

BRIEF-BTG trading in line, guides revenue to 510-£540 mln stg on FX

* Overall performance and trading since 1 april 2016 are in line with expectations

14 Jul 2016

UPDATE 1-BTG Group FY profit doubles, sees 8-15 pct rev growth

(Adds forecast, analyst comment, share movement) May 17 British healthcare group BTG Plc said its full-year pretax profit doubled from a year earlier as sales of its interventional therapies picked up, and forecast an 8-15 percent revenue growth for the next year. BTG shares rose as much as 2.4 percent to 600.50 pence on Tuesday morning. BTG said it expected revenue to be in the range 485 million pounds to 515 million pounds ($703.6 million-$746.7 million) for the fin

17 May 2016

BTG Group FY pretax profit doubles

May 17 British healthcare group BTG said its full-year pretax profit doubled from a year earlier on strong revenue growth.

17 May 2016

BRIEF-Galil medical announces agreement to acquisition by Btg Plc

* Galil Medical announces agreement to acquisition by Btg Plc Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)

06 May 2016

Britain's BTG buys tumor freezing company Galil Medical

LONDON British healthcare group BTG said is had agreed to buy Galil Medical, a U.S. company that makes cryoablation products to treat Kidney and other cancers by freezing and destroying tumors, for an initial cash payment of $84.5 million.

06 May 2016

Earnings vs. Estimates